Correlation Between Karyopharm Therapeutics and CEL SCI

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and CEL SCI at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and CEL SCI into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and CEL SCI Corp, you can compare the effects of market volatilities on Karyopharm Therapeutics and CEL SCI and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of CEL SCI. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and CEL SCI.

Diversification Opportunities for Karyopharm Therapeutics and CEL SCI

0.22

Correlation Coefficient

Karyopharm Therapeutics  CEL SCI

Modest diversification

The 3 months correlation between Karyopharm and CEL is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and CEL SCI Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CEL SCI Corp and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with CEL SCI. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CEL SCI Corp has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and CEL SCI go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and CEL SCI

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to generate 0.62 times more return on investment than CEL SCI. However, Karyopharm Therapeutics is 1.61 times less risky than CEL SCI. It trades about -0.06 of its potential returns per unit of risk. CEL SCI Corp is currently generating about -0.08 per unit of risk. If you would invest  83.00  in Karyopharm Therapeutics on September 28, 2024 and sell it today you would lose (17.52) from holding Karyopharm Therapeutics or give up 21.11% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  CEL SCI Corp

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

CEL SCI Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CEL SCI Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Karyopharm Therapeutics and CEL SCI

The main advantage of trading using opposite Karyopharm Therapeutics and CEL SCI positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, CEL SCI can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CEL SCI will offset losses from the drop in CEL SCI's long position.

The idea behind Karyopharm Therapeutics and CEL SCI Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.